Acyl-CoA:Cholesterol Acyltransferase Inhibition Reduces Atherosclerosis in Apolipoprotein E—Deficient Mice
暂无分享,去创建一个
J. Badimón | J. Fallon | E. A. Fisher | J. Kusunoki | K. Aragane | Jun Kusunoki | Katsumi Aragane | Dipal K. Hansoty | Dipal K. Hansoty
[1] H. Brewer. The lipid-laden foam cell: an elusive target for therapeutic intervention. , 2000, The Journal of clinical investigation.
[2] Robert V Farese,et al. Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1. , 2000, The Journal of clinical investigation.
[3] H. Kozono,et al. Postprandial hyperlipidemia in streptozotocin-induced diabetic rats is due to abnormal increase in intestinal acyl coenzyme A:cholesterol acyltransferase activity. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[4] T. Major,et al. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[5] P. Bachorik,et al. Novel effects of the acyl-coenzyme A:Cholesterol acyltransferase inhibitor 58-035 on foam cell development in primary human monocyte-derived macrophages. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[6] P. Yancey,et al. Crystallization of free cholesterol in model macrophage foam cells. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[7] R. Anderson,et al. Acyl-coenzyme A:cholesteryl acyltransferase 2. , 1999, Current opinion in lipidology.
[8] H. Ohnishi,et al. Effects of F-1394, an acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, on ACAT activity in HepG2 cells and on hepatic secretion of lipids in Triton WR-1339-induced hyperlipidemic rats: possible role of hepatic ACAT in very low density lipoprotein secretion. , 1998, Japanese journal of pharmacology.
[9] E. Braunwald. Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. , 1997, The New England journal of medicine.
[10] I. Tabas. Free cholesterol-induced cytotoxicity a possible contributing factor to macrophage foam cell necrosis in advanced atherosclerotic lesions. , 1997, Trends in cardiovascular medicine.
[11] H. Ohnishi,et al. [Hypolipidemic action of F-1394, an acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor, in high-fat diet fed beagle dogs]. , 1997, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.
[12] T. Chang,et al. Acyl-coenzyme A:cholesterol acyltransferase. , 1997, Annual review of biochemistry.
[13] Richard T. Lee,et al. Macrophages and atherosclerotic plaque stability , 1996, Current opinion in lipidology.
[14] P. Milos,et al. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[15] F. Ito,et al. Effect of FR145237, a novel ACAT inhibitor, on atherogenesis in cholesterol-fed and WHHL rabbits. Evidence for a direct effect on the arterial wall. , 1995, Biochimica et biophysica acta.
[16] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[17] H. Ohnishi,et al. Hypocholesterolemic action and prevention of cholesterol absorption via the gut by F-1394, a potent acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, in cholesterol diet-fed rats. , 1995, Japanese journal of pharmacology.
[18] V. Fuster,et al. Coronary plaque disruption. , 1995, Circulation.
[19] H. Ohnishi,et al. Studies on acyl-CoA: cholesterol acyltransferase (ACAT) inhibitory effects and enzyme selectivity of F-1394, a pantotheic acid derivative. , 1995, Japanese journal of pharmacology.
[20] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.
[21] V. Fuster,et al. Macrophage Infiltration in Acute Coronary Syndromes: Implications for Plaque Rupture , 1994, Circulation.
[22] T. Bocan,et al. Comparison of CI-976, an ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions. A biochemical, morphological, and morphometric evaluation. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.
[23] D. Sliskovic,et al. Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents. , 1991, Trends in pharmacological sciences.
[24] R. Ross. The pathogenesis of atherosclerosis--an update. , 1986, The New England journal of medicine.
[25] M. Brown,et al. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. , 1983, Annual review of biochemistry.
[26] D. C. Sheehan,et al. Theory and Practice of Histotechnology , 1980 .